Fluconazole and voriconazole dosage in Urosepsis
Reading File
Finding Sources
Finding Sources
Searching PubMed
fluconazole voriconazole urosepsis candiduria treatment
Searching the Web
fluconazole voriconazole dosage urosepsis candida UTI 2024 guidelines
Reading File
Finding Sources
I now have excellent data from multiple authoritative sources. Let me compile the full answer.
Fluconazole and Voriconazole in Urosepsis (Fungal/Candida)
Urosepsis of fungal origin is most commonly caused by Candida spp. The choice of antifungal, dose, and duration depends on the Candida species, site of infection (cystitis vs. pyelonephritis/upper tract), renal function, and susceptibility.
FLUCONAZOLE
Drug of choice for Candida UTI/urosepsis (fluconazole-susceptible species)
Fluconazole is excreted in its active form in the urine and achieves urine concentrations that far exceed the MIC for most Candida spp. This makes it the cornerstone agent.
| Indication | Dose | Duration |
|---|---|---|
| Symptomatic cystitis / pyelonephritis (fluconazole-susceptible) | Loading dose: 400 mg on Day 1, then 200 mg/day orally | 14 days |
| Upper tract disease / pyelonephritis | 200-400 mg/day orally | 14 days |
| C. glabrata (dose-dependent susceptibility) | Up to 800 mg/day if MIC permits | 14 days |
| Localized fungal UTI (EAU Guidelines) | 200 mg/day orally | 2 weeks |
Renal dose adjustment (critical in urosepsis with AKI):
- CrCl 20-50 mL/min: reduce dose by 50%
- CrCl <20 mL/min: reduce dose by 75%
- Dialysis patients: full dose 3x weekly, after each dialysis session
- Comprehensive Clinical Nephrology, 7th Ed., p. 787
- EAU Guidelines on Urological Infections
- IDSA Candidiasis Guidelines 2016
Key limitation: Fluconazole does not effectively treat C. krusei (intrinsically resistant), and many C. glabrata infections fail to respond (up to 30% resistance rates).
VORICONAZOLE
NOT recommended for Candida UTI or urosepsis
This is a critical clinical point:
"The other available azole agents, itraconazole, voriconazole, posaconazole, and isavuconazole, are not excreted into the urine as active drug. Whether tissue concentrations might be high enough to treat invasive kidney or bladder infections is not known, but there is little clinical experience to suggest that they will be effective."
- Comprehensive Clinical Nephrology, 7th Ed.
The IDSA guidelines state explicitly:
"Voriconazole does not accumulate in active form in the urine and thus should not be used for urinary candidiasis."
The 2026 management review also confirms: "Echinocandins and mold-active azoles (e.g., voriconazole, posaconazole) generally do not achieve adequate urinary concentrations."
Voriconazole is used for Candida infections only as:
- Step-down oral therapy for invasive candidiasis (non-urinary sites) due to C. krusei or fluconazole-resistant, voriconazole-susceptible C. glabrata
- Adult oral dosing for candidiasis (non-urinary): Loading 400 mg q12h x2 doses, then 200 mg q12h maintenance
Alternatives When Fluconazole Fails or Is Contraindicated
| Drug | Indication | Dose |
|---|---|---|
| Amphotericin B deoxycholate (NOT liposomal) | Upper tract/pyelonephritis, fluconazole failure, C. krusei | 0.3-0.6 mg/kg/day IV for 1-7 days (up to 2 weeks for complicated upper tract) |
| Flucytosine (5-FC) | Fluconazole-resistant UTI (not for pyelonephritis alone) | 25 mg/kg orally every 6 hours x 7-10 days |
| Bladder irrigation - AmB | Local cystitis only | 200 mg/L in 100 mL 5% glucose, 3x daily x 7 days |
Note: Liposomal amphotericin B does not reach the urine in adequate concentrations - deoxycholate formulation must be used for urinary infections.
Clinical Pearls for Urosepsis Management
- Source control first - remove or replace indwelling catheters, relieve obstruction; catheter removal alone eradicates candiduria in many patients.
- Identify species - always send urine culture with susceptibility testing, especially for non-albicans Candida.
- Asymptomatic candiduria in non-high-risk patients generally does not require systemic antifungal treatment.
- Fluconazole is concentrated in urine - even C. glabrata with MIC up to 64 µg/mL may respond because urinary drug levels exceed 100 µg/mL.
- Voriconazole has no role in urinary candidiasis regardless of species susceptibility.
This is a shared conversation. Sign in to Orris to start your own chat.